BlackRock Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

BlackRock Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$244K	Buy	38,500 +614	+2%	+$3.19K	﹤0.01%	2614
2016 Q3	$167K	Buy	37,886 +4,772	+14%	+$19.1K	﹤0.01%	2776
2016 Q2	$94K	Buy	33,114 +1,809	+6%	+$5.62K	﹤0.01%	2997
2016 Q1	$89K	Buy	31,305 +823	+3%	+$3.65K	﹤0.01%	2968
2015 Q4	$315K	Sell	30,482 -15,158	-33%	-$151K	﹤0.01%	2331
2015 Q3	$520K	Sell	45,640 -314,953	-87%	-$4.2M	﹤0.01%	2164
2015 Q2	$5.38M	Buy	360,593 +10,798	+3%	+$123K	0.01%	976
2015 Q1	$3.16M	Buy	349,795 +6,689	+2%	+$69.3K	﹤0.01%	1079
2014 Q4	$4.17M	Sell	343,106 -1,893	-0.5%	-$20.9K	﹤0.01%	1018
2014 Q3	$3.38M	Sell	344,999 -22,891	-6%	-$281K	﹤0.01%	1055
2014 Q2	$4.69M	Buy	367,890 +357,957	+3,604%	+$3.48M	﹤0.01%	986
2014 Q1	$105K	Hold	9,933	–	–	﹤0.01%	3007
2013 Q4	$75K	Buy	9,933 +1,226	+14%	+$7.76K	﹤0.01%	3148
2013 Q3	$63K	Buy	8,707 +468	+6%	+$2.37K	﹤0.01%	3126
2013 Q2	$13K	Buy	+8,239	New	+$14.2K	﹤0.01%	3346

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's BCRX Position: Q4 2016 in Review

BlackRock Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 1.6% in Q4 2016, buying an estimated $3.19K and bringing the position to 38,500 shares worth $244K. The position accounts for ﹤0.01% of the portfolio, ranked #2614.

BlackRock Advisors first reported a position in BCRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $5.38M in Q2 2015. 112 funds tracked by Wall St. Rank hold BCRX as of Q4 2016.

BlackRock Advisors held 38,500 shares of BioCryst Pharmaceuticals worth $244K as of Q4 2016.
BlackRock Advisors bought 614 BioCryst Pharmaceuticals shares in Q4 2016, an estimated $3.19K.
BioCryst Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2614 holding.
BlackRock Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's BioCryst Pharmaceuticals position peaked at $5.38M in Q2 2015.
112 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.